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Introduction
Trauma is one of the leading causes of mortality world-
wide, resulting in a great global burden of disability and
mortality [1,2]. Approximately half of all trauma deaths
occur during the first hours due to traumatic brain injury
or massive bleeding. Later deaths are due to, for example,
sepsis or multiple organ failure [3]. Independent risk
factors for post-injury sepsis are still somewhat poorly
defined. Injury Severity Score (ISS), male gender, age, low
Glasgow Coma Scale (GCS) and massive blood transfusion
have been suggested as risk factors [4].
Thioredoxin (TRX) is thought to have important anti-
oxidant properties but it also functions as an endogenous
anti-inflammatory mediator [5]. The link between high
plasma levels of TRX and sepsis has been studied
previously, although with conflicting evidence [5,6].
TRX-levels in trauma patients and the possible correlation
to secondary complications such as post-injury sepsis and
acute respiratory distress syndrome (ARDS) have to our
knowledge not been studied previously.
Objectives
To study the relationship between trauma and plasma
levels of TRX as well as the possible correlation between
post-traumatic plasma-TRX and secondary outcomes
such as severe sepsis and ARDS.
Methods
ICU-admitted trauma patients with an expected stay of
>3 days (n = 84) were included. Median ISS was 29.
Plasma-TRX was analyzed on day 1 and 3. Clinical,
physiological and outcome data were retrieved from the
trauma and ICU research registries. In addition, we
analyzed plasma-TRX in 10 healthy subjects.
Results
A three-fold increase in day 1 plasma-TRX was seen in
trauma patients when compared to healthy volunteers
(median, IQR 63.9 ng/ml, 39.3-114.6 vs. 22.6 ng/ml,
16.1-25.8 p = 0.0001). High ISS (>25) was associated with
high plasma-TRX (median, IQR 72.1 ng/ml, 45.2-129.3 vs.
47.9 ng/ml, 35.0-81.2 p = 0.049).
TRX decreased significantly between day 1 and 3
(median, IQR 63.9 ng/ml, 39.3-114.6 vs. 38.6 ng/ml,
32.4-57.1 p < 0.0001).
There was no significant difference between survivors
and non-survivors in plasma-TRX.
Day 1 plasma-TRX levels were significantly increased in
patients who later developed severe sepsis compared to
those who did not (median, IQR 72.9 ng/ml, 44.8-137.3 vs.
49.8 ng/ml, 39.0-78.3 p = 0.014), no such difference was
noted for post-injury ARDS.
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Conclusions
TRX levels rise after trauma. Increased plasma-TRX levels
are associated with post-injury sepsis. The potential
usefulness of TRX as a biomarker in trauma patients
needs further evaluation in larger studies.
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